眼科 ›› 2012, Vol. 21 ›› Issue (4): 222-227.

• 述评 • 上一篇    下一篇

视网膜中央静脉阻塞继发黄斑水肿的治疗进展—从临床试验到临床实践

张永鹏   彭晓燕   

  1. 100730首都医科大学附属北京同仁医院 北京同仁眼科中心 北京市眼科学与视觉科学重点实验室
  • 收稿日期:2012-06-05 出版日期:2012-07-25 发布日期:2012-07-27
  • 通讯作者: 彭晓燕,Email:drpengxy@gmail.com

The advance in treatment of macular edema secondary to central retinal vein occlusion—from clinical trial to clinical practice

ZHANG Yong-peng, PENG Xiao-yan.   

  1. Beijing Ophthalmology and Visual Science Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2012-06-05 Online:2012-07-25 Published:2012-07-27
  • Contact: PENG Xiao-yan, Email: drpengxy@gmail.com

摘要: 【摘要】 视网膜中央静脉阻塞(CRVO)是常见的威胁视力的视网膜血管疾病,其病因复杂,临床上针对其并发症黄斑水肿的治疗亦较为棘手。近年来,有较多CRVO治疗的新探索。在药物治疗方面,有抗血管内皮生长因子(VEGF)药物包括Bevacizumab、Ranibizumab、Pegaptanib和VEGF Trap-Eye,曲安奈德和玻璃体内植入药物缓释系统如醋酸氟轻松(Retisert)和地塞米松(Ozurdex)。在激光和手术治疗效果方面也有一些探索。目前仍有一些大型多中心随机临床研究正在进行中。尽管已有循征医学证据验证了某些疗法的有效性和安全性,但从临床试验到临床实践,仍有相当多的具体问题需要解决。(眼科,2012,21:222-227)

关键词: 视网膜中央静脉阻塞, 黄斑水肿/治疗, 临床试验, 循征医学

Abstract: 【Abstract】 Central retinal vein occlusion (CRVO) is a common, sight-threatening retinal vascular disorders. The etiology of CRVO is complicated and current treatments for CRVO and its sequelae such as macular edema are still tough. However, there are many emerging treatments in recently years. Intravitreal pharmacologic agents which include anti-vascular endothelial growth factor (Bevacizumab, Ranibizumab, Pegaptanib, and VEGF Trap-Eye), triamcinolone acetonide and sustained delivery corticosteroid device (fluocinolone acetonide and dexamethasone) are promising. There are also some researches on the efficiency of laser and surgery. Several large, well-designed, prospective, randomized controlled trials are still ongoing worldwidely. Although the efficiency and safety of some treatments have been proved by evidence-based medicine, there are still lots of questions which should be answered on the way from clinical trial to clinical practice. (Ophthalmol CHN, 2012, 21: 222-227)

Key words:  central retinal vein occlusion, macular edema/therapy, clinical trial, evidence-based medicine